Solitomab (AMG 110) is a bispecific anti-CD3 and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer. In Vitro Solitomab (1 μg/mL; 4 hours) shows cytotoxicity to EpCAM-positive cell lines and increases the sensibility of EpCAM positive carcinosarcomas (CS) cells to T-cell-cytotoxicity. Solitomab (7 days) increases the expression level of CD25 and HLA-DR protein (T-cell activation markers) on CD8 + and CD4 + T cells. Solitomab (0-2.5 μg/mL; 4 hours) is cytotoxic to ovarian carcinoma cells and the 1 μg/mL dose shows the best tumor killing effects. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Liquid